Sort
78,016 grants matching “breast cancer”
Mechanisms of tumor cell clustering in breast cancer metastasis
$462,861Chonghui Cheng · Baylor College Of Medicine · R01 · FY2023 · CA
Novel MUC1 Theranostic Peptides for Imaging and Treatment of Triple-Negative Breast Cancer
$462,860Corinne Beinat · Stanford University · R37 · FY2024 · CA
Cost-Effectiveness--Treatments--Ductal Carcinoma In Situ
$462,802University Of Rochester · R01 · FY2003 · CA
Quantitative MRI for Predicting Response of Breast Cancer to Neoadjuvant Therapy
$462,791Richard G Abramson · Vanderbilt University Medical Center · U01 · FY2016 · CA
Role of Apobecs in Retroviral Immunity
$462,755Jaquelin Page Dudley · University Of Texas At Austin · R01 · FY2017 · AI
Clinical production of viral vectors for cancer gene therapy
$462,714Rachel Beyer · Division Of Basic Sciences - Nci · ZIC · FY2021 · CA
Targeting ferroptosis in aggressive subtypes of lung cancer
$462,704Triparna Sen · Ohio State University · R01 · FY2025 · CA
Engineered hybrid aging model for disease progression
$462,702Pinar Zorlutuna · University Of Notre Dame · R01 · FY2025 · CA
Tumor maintenance and development in mouse models
$462,696Harold E Varmus · Sloan-Kettering Inst Can Research · U01 · FY2006 · CA
Research Project 1: Identification and validation of efficacious therapies for breast cancer using patient-derived specimens
$462,687Alana L Welm · University Of Utah · U54 · FY2019 · CA
IBCSG STATISTICAL CENTER--A BREAST CANCER STUDY RESOURCE
$462,685Richard D Gelber · Dana-Farber Cancer Inst · U24 · FY2008 · CA
Microendoscopic Electrical Impedance Sensing for Real-time Intraoperative Surgical Margin Assessment
$462,685Ryan Joseph Halter · Dartmouth College · R01 · FY2024 · CA
KANSAS CITY COMMUNITY CLINICAL ONCOLOGY PROGRAM
$462,683Kansas City Clinical Oncology Program · U10 · FY2000 · CA
Analyzer-based Phase Contrast Imaging System Development and Evaluation
$462,668Jovan G Brankov · Illinois Institute Of Technology · R01 · FY2021 · EB
Leveraging the metastatic tumor stroma to limit breast cancer progression
$462,667Sheila A Stewart · Washington University · R01 · FY2025 · CA
Use of CTEP portfolio compounds to counteract phenotype conversion in GBM
$462,651Frank Pajonk · University Of California Los Angeles · R01 · FY2022 · CA
Use of CTEP portfolio compounds to counteract phenotype conversion in GBM
$462,651Frank Pajonk · University Of California Los Angeles · R01 · FY2025 · CA
NOVEL DNA DOUBLE STRAND BREAK REPAIR TARGETING THERAPEUTICS FOR CANCER TREATMENT
$462,633Barry P Sleckman · Washington University · R01 · FY2014 · CA
Comparative modeling of multiple myeloma across myeloma control continuuum: prevention, treatment, and disparity reduction
$462,628Su-Hsin Chang · Washington University · U01 · FY2024 · CA
Pentraxin-3 in the Pathogenesis and Management of Triple-Negative Breast Cancer
$462,614Antoine Elias Karnoub · Beth Israel Deaconess Medical Center · R01 · FY2025 · CA
A novel therapy for HER2 positive hormone refractory breast cancer
$462,585Anne W Hamburger · University Of Maryland Baltimore · RC1 · FY2010 · CA
Causes and Consequences of Whole Genome Duplication in Cancer Progression and Acquired Drug Resistance
$462,570Sergi Regot · Johns Hopkins University · R01 · FY2025 · CA
DOXORUBICIN CARDIOMYOPATHY: MOLECULAR GENETICS &RESCUE
$462,487University Of Southern California · R01 · FY2002 · HL
Mechanical Regulation of Tumor Angiogenesis
$462,422Cynthia A Reinhart-King · Vanderbilt University · R01 · FY2019 · HL
Defining and Targeting Homologous Recombination Deficiency in Breast Cancer
$462,413Simon N Powell · Sloan-Kettering Inst Can Research · P50 · FY2020 · CA